You are here

Article info

Article menu

Download PDFPDF

Immunotherapy biomarkers
Original research
B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC

Authors

  • Xin Xing Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China Shanghai University of Medicine and Health Sciences Affiliated Sixth People’s Hospital South Campus, Shanghai, China PubMed articlesGoogle scholar articles
  • Shi-Qi Yin Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China PubMed articlesGoogle scholar articles
  • Xia-Qing Li Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China PubMed articlesGoogle scholar articles
  • Hui Li State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  • Hong-Tai Ma Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China PubMed articlesGoogle scholar articles
  • Aziguli Tulamaiti State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  • Shu-Yu Xiao State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  • Yu-Tong Liu The First Hospital of Jilin University, Changchun, Jilin, China PubMed articlesGoogle scholar articles
  • Hao Zhang Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  • Zhigang Zhang State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  • Yan-Miao Huo Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  • Xiao-Mei Yang State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  • Yan Yang State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  • Xue-Li Zhang Shanghai University of Medicine and Health Sciences Affiliated Sixth People’s Hospital South Campus, Shanghai, China State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Xue-Li Zhang; xlzhang{at}shsci.org; Dr Yan Yang; yangyang201298{at}163.com; Dr Xiao-Mei Yang; xmyang{at}shsci.org; Dr Yan-Miao Huo; huoyanmiao{at}126.com
View Full Text

Citation

Xing X, Yin S, Li X, et al
B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC
Journal for ImmunoTherapy of Cancer 2025;13:e010908. doi: 10.1136/jitc-2024-010908

Publication history

  • Accepted April 17, 2025
  • First published May 2, 2025.
Online issue publication 
May 02, 2025

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.